New World Angels Invests in Epion Therapeutics
BOCA RATON, FL (SEP 12, 2025) – New World Angels (“NWA”), a leading Florida-based structured angel investment organization, announced today that it completed an investment of $425,500 into Epion Therapeutics as part of a $18.5MM Convertible Note round. Epion Therapeutics is a clinical-stage biotechnology company focused on developing innovative, minimally-invasive treatments for corneal diseases, primarily targeting keratoconus and ectatic corneal disorders. Their flagship product, EpiSmart™, is a transformative epithelium-on cross-linking system designed to strengthen the cornea without disrupting the epithelium, enabling simultaneous treatment of both eyes with significantly reduced patient discomfort and recovery time compared to current standards of care. Epion’s approach aims to provide earlier intervention, improving outcomes for millions of patients worldwide who suffer from progressive corneal conditions. Headquartered in Burlington, Massachusetts, Epion is led by a team of seasoned experts in ophthalmology and life sciences.
“Epion Therapeutics represents an exciting advancement in ophthalmic care with its innovative, minimally invasive treatment for corneal diseases. We are proud to support a company that aligns with our mission to back transformative healthcare ventures with the potential to significantly improve patient outcomes. Our investment reflects confidence in Epion’s leadership and technology as they move toward commercialization and broader market impact.” - Dr. David Schimel, NWA Director and Healthcare Investment Co-Chair.
“We are excited to have New World Angels support our effort to complete our Phase 3 trial program and move rapidly to submission for FDA approval. EpiSmart has the potential to save the vision of millions of young people across the globe affected by keratoconic disease.”-Michael D. Webb, President and CEO, Epion Therapeutics, Inc.
About Epion Therapeutics:
Epion is developing EpiSmart, a minimally-invasive treatment for keratoconus and ectatic corneal disease that could bring early intervention to millions of patients globally. Their approach is a transformative cross-linking system designed to treat keratoconus on initial diagnosis without disruption of the epithelium, allowing for a rapid return to normal activities.
About New World Angels: New World Angels (NWA) is a group of 100+ accredited, private investors, operators, and entrepreneurs dedicated to providing equity capital and guidance to early-stage entrepreneurial companies, especially those with a strong presence in Florida. Members of NWA have extensive experience in founding, building, and managing companies in various industries. NWA members are involved in entrepreneurial communities from Miami to Melbourne on Florida’s east coast and from Naples to Orlando on Florida’s west coast. NWA has invested over $30 million in innovative start-ups. In addition to providing funding, NWA members make their expertise and resource networks available to portfolio companies to facilitate a company’s growth.
Participating In New World Angels Investments
Founders can apply for funding at https://www.newworldangels.com. Accredited investors and family offices seeking access to curated early stage investments can reach out to New World’s Managing Director, Jessica Miley at jessica@newworldangels.com.
Media Contact:
Jessica Miley
Managing Director, New World Angels
(617) 504-1864
Jessica@newworldangels.com